Clinical Trial Update: IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating IBI-354 with or without pertuzumab versus a standard regimen of taxane, trastuzumab and pertuzumab in HER2-positive breast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBI-354 (IBI-354)
• Pertuzumab (pertuzumab)
• Taxane (class) (taxane)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: RECRUITING